xupper22的个人主页 - 老虎社区

xupper22

xupper22

暂无个人介绍

IP属地：未知

8关注

6粉丝

2主题

0勋章

2021-12-08

Anything coming from Pfizer is bs at this point. We need actual peer reviewed studies published publicly from actual scientists for accurate information. This is just them winning back the market's confidence and persuading nations to order 3rd jabs for more profit$.

Pfizer, BioNTech say third dose neutralizes Omicron variant

2021-12-06

$Roundhill Ball Metaverse ETF(META)$Don't panic amongst commoner fears. Buy the dip.

2021-12-06

Speculation play...

抱歉，原内容已删除

2021-11-08

Last November?! Where was this in mainstream media all this time?!

抱歉，原内容已删除

2021-11-04

The more truth about this covid situation gets spread out there, the more big corrupt pharmas should dive in the short term.

抱歉，原内容已删除

2021-10-30

Niiice

@小虎活动:[Halloween Game] Trade or Treat!

2021-10-30

$ABF SG BOND ETF(A35.SI)$sg is garbage

2021-10-28

Seriously last night insider pump and dump? $AST SpaceMobile, Inc.(ASTS)$

2021-10-21

Like near you

抱歉，原内容已删除

2021-10-01

Rather great news. First aim is to tahan the rest of this year in SG without getting jabbed.

Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News

2021-09-24

$STI ETF(ES3.SI)$bloodshed

2021-05-13

$Viomi Technology Co.(VIOT)$[流泪]

2021-05-07

$FIRST SHIP LEASE TRUST(D8DU.SI)$[流泪]

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3579827147050987,"uuid":"3579827147050987","gmtCreate":1616733122995,"gmtModify":1620384637938,"name":"xupper22","pinyin":"xupper22","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":8,"tweetSize":26,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":602303058,"gmtCreate":1638966793507,"gmtModify":1638968906662,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Anything coming from Pfizer is bs at this point. We need actual peer reviewed studies published publicly from actual scientists for accurate information. This is just them winning back the market's confidence and persuading nations to order 3rd jabs for more profit$.","listText":"Anything coming from Pfizer is bs at this point. We need actual peer reviewed studies published publicly from actual scientists for accurate information. This is just them winning back the market's confidence and persuading nations to order 3rd jabs for more profit$.","text":"Anything coming from Pfizer is bs at this point. We need actual peer reviewed studies published publicly from actual scientists for accurate information. This is just them winning back the market's confidence and persuading nations to order 3rd jabs for more profit$.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602303058","repostId":"1177589023","repostType":2,"repost":{"id":"1177589023","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohu8.com/m/news/1177589023?lang=&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1},"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606014353,"gmtCreate":1638801265327,"gmtModify":1638801265468,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/META\">$Roundhill Ball Metaverse ETF(META)$</a>Don't panic amongst commoner fears. Buy the dip.","listText":"<a href=\"https://laohu8.com/S/META\">$Roundhill Ball Metaverse ETF(META)$</a>Don't panic amongst commoner fears. Buy the dip.","text":"$Roundhill Ball Metaverse ETF(META)$Don't panic amongst commoner fears. Buy the dip.","images":[{"img":"https://static.tigerbbs.com/b0e398f47591254152b057b8cb9f72fa","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606014353","isVote":1,"tweetType":1,"viewCount":649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":608798676,"gmtCreate":1638787262028,"gmtModify":1638787262432,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Speculation play...","listText":"Speculation play...","text":"Speculation play...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608798676","repostId":"1191547402","repostType":2,"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844019974,"gmtCreate":1636376601266,"gmtModify":1636376649125,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Last November?! Where was this in mainstream media all this time?!&nbsp;","listText":"Last November?! Where was this in mainstream media all this time?!&nbsp;","text":"Last November?! Where was this in mainstream media all this time?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844019974","repostId":"1141245956","repostType":2,"isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848709368,"gmtCreate":1636025415150,"gmtModify":1636027785724,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"The more truth about this covid situation gets spread out there, the more big corrupt pharmas should dive in the short term.&nbsp;","listText":"The more truth about this covid situation gets spread out there, the more big corrupt pharmas should dive in the short term.&nbsp;","text":"The more truth about this covid situation gets spread out there, the more big corrupt pharmas should dive in the short term.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848709368","repostId":"1114412462","repostType":2,"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840946057,"gmtCreate":1635580088005,"gmtModify":1635580088005,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Niiice","listText":"Niiice","text":"Niiice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840946057","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840084280,"gmtCreate":1635568727401,"gmtModify":1635568743175,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/A35.SI\">$ABF SG BOND ETF(A35.SI)$</a>sg is garbage","listText":"<a href=\"https://laohu8.com/S/A35.SI\">$ABF SG BOND ETF(A35.SI)$</a>sg is garbage","text":"$ABF SG BOND ETF(A35.SI)$sg is garbage","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840084280","isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855596967,"gmtCreate":1635381615759,"gmtModify":1635381615823,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Seriously last night insider pump and dump?&nbsp;<a href=\"https://laohu8.com/S/ASTS\">$AST SpaceMobile, Inc.(ASTS)$</a>","listText":"Seriously last night insider pump and dump?&nbsp;<a href=\"https://laohu8.com/S/ASTS\">$AST SpaceMobile, Inc.(ASTS)$</a>","text":"Seriously last night insider pump and dump? $AST SpaceMobile, Inc.(ASTS)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855596967","isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853129068,"gmtCreate":1634781048703,"gmtModify":1634781051103,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like near you","listText":"Like near you","text":"Like near you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853129068","repostId":"1181020907","repostType":4,"isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864653997,"gmtCreate":1633099274018,"gmtModify":1633099274187,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Rather great news. First aim is to tahan the rest of this year in SG without getting jabbed.","listText":"Rather great news. First aim is to tahan the rest of this year in SG without getting jabbed.","text":"Rather great news. First aim is to tahan the rest of this year in SG without getting jabbed.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864653997","repostId":"2172968435","repostType":4,"repost":{"id":"2172968435","pubTimestamp":1633097043,"share":"https://www.laohu8.com/m/news/2172968435?lang=&edition=full","pubTime":"2021-10-01 22:04","market":"us","language":"en","title":"Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News","url":"https://stock-news.laohu8.com/highlight/detail?id=2172968435","media":"Investing.com","summary":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in pre","content":"<p>By Geoffrey Smith</p>\n<p>Investing.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.</p>\n<p>By (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.&nbsp; Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.</p>\n<p>Merck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.</p>\n<p>The study was stopped early, as is often the case when an experimental drug shows signs of efficacy.</p>\n<p>Scientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.</p>\n<p>Related Articles</p>\n<p>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</p>\n<p>Stocks under pressure as euro zone inflation hits 13-year high</p>\n<p>Merck's COVID-19 pill cuts risk of death, hospitalization by 50% in study</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","MRK":"默沙东","NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2172968435","content_text":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.\nBy (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.  Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.\nMerck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.\nThe study was stopped early, as is often the case when an experimental drug shows signs of efficacy.\nScientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.\nRelated Articles\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\nStocks under pressure as euro zone inflation hits 13-year high\nMerck's COVID-19 pill cuts risk of death, hospitalization by 50% in study","news_type":1},"isVote":1,"tweetType":1,"viewCount":461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861696598,"gmtCreate":1632490537414,"gmtModify":1632717966740,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>bloodshed","listText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>bloodshed","text":"$STI ETF(ES3.SI)$bloodshed","images":[{"img":"https://static.tigerbbs.com/ce8180f7add6d5d3a728b0731b072ed7","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861696598","isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":191943320,"gmtCreate":1620836935760,"gmtModify":1631888757214,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VIOT\">$Viomi Technology Co.(VIOT)$</a>[流泪]&nbsp;","listText":"<a href=\"https://laohu8.com/S/VIOT\">$Viomi Technology Co.(VIOT)$</a>[流泪]&nbsp;","text":"$Viomi Technology Co.(VIOT)$[流泪]","images":[{"img":"https://static.tigerbbs.com/0e0c80ecfd4fab811596505698014851","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/191943320","isVote":1,"tweetType":1,"viewCount":1276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":104694641,"gmtCreate":1620382122583,"gmtModify":1631889131093,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/D8DU.SI\">$FIRST SHIP LEASE TRUST(D8DU.SI)$</a>[流泪]&nbsp;","listText":"<a href=\"https://laohu8.com/S/D8DU.SI\">$FIRST SHIP LEASE TRUST(D8DU.SI)$</a>[流泪]&nbsp;","text":"$FIRST SHIP LEASE TRUST(D8DU.SI)$[流泪]","images":[{"img":"https://static.tigerbbs.com/6efc4b6dfecf2867683b81dd725c1069","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/104694641","isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":844019974,"gmtCreate":1636376601266,"gmtModify":1636376649125,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Last November?! Where was this in mainstream media all this time?!&nbsp;","listText":"Last November?! Where was this in mainstream media all this time?!&nbsp;","text":"Last November?! Where was this in mainstream media all this time?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844019974","repostId":"1141245956","repostType":2,"repost":{"id":"1141245956","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://www.laohu8.com/m/news/1141245956?lang=&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron&nbsp;shares&nbsp;rose&nbsp;2.2%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown&nbsp;an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regeneron&nbsp;shares&nbsp;rose&nbsp;2.2%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown&nbsp;an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1},"isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606014353,"gmtCreate":1638801265327,"gmtModify":1638801265468,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/META\">$Roundhill Ball Metaverse ETF(META)$</a>Don't panic amongst commoner fears. Buy the dip.","listText":"<a href=\"https://laohu8.com/S/META\">$Roundhill Ball Metaverse ETF(META)$</a>Don't panic amongst commoner fears. Buy the dip.","text":"$Roundhill Ball Metaverse ETF(META)$Don't panic amongst commoner fears. Buy the dip.","images":[{"img":"https://static.tigerbbs.com/b0e398f47591254152b057b8cb9f72fa","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606014353","isVote":1,"tweetType":1,"viewCount":649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":104694641,"gmtCreate":1620382122583,"gmtModify":1631889131093,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/D8DU.SI\">$FIRST SHIP LEASE TRUST(D8DU.SI)$</a>[流泪]&nbsp;","listText":"<a href=\"https://laohu8.com/S/D8DU.SI\">$FIRST SHIP LEASE TRUST(D8DU.SI)$</a>[流泪]&nbsp;","text":"$FIRST SHIP LEASE TRUST(D8DU.SI)$[流泪]","images":[{"img":"https://static.tigerbbs.com/6efc4b6dfecf2867683b81dd725c1069","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/104694641","isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":608798676,"gmtCreate":1638787262028,"gmtModify":1638787262432,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Speculation play...","listText":"Speculation play...","text":"Speculation play...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608798676","repostId":"1191547402","repostType":2,"repost":{"id":"1191547402","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638783371,"share":"https://www.laohu8.com/m/news/1191547402?lang=&edition=full","pubTime":"2021-12-06 17:36","market":"us","language":"en","title":"CF Acquisition Corp VI stock jumped 31% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1191547402","media":"Tiger Newspress","summary":"CF Acquisition Corp VI stock jumped 31% in premarket trading as YouTube competitor Rumble would go p","content":"<p>CF Acquisition Corp VI stock jumped 31% in premarket trading&nbsp;as&nbsp;YouTube competitor Rumble&nbsp;would&nbsp;go public via SPAC CF Acquisition VI.</p>\n<p><img src=\"https://static.tigerbbs.com/b8dc893dd9a925f906f6e5709286bb79\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Canadian video platform Rumble Inc said&nbsp;it would go public by merging with blank-check firm&nbsp;CF Acquisition Corp VI&nbsp;at an initial enterprise value of $2.1 billion.</p>\n<p>The deal is expected to provide about $400 million in proceeds to Rumble, the company said in a statement.</p>\n<p>Upon the deal's closing, Rumble said founder and Chief Executive Officer Chris Pavlovski will retain voting control.</p>\n<p>The combined company will be called Rumble and is expected to list on the Nasdaq.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF Acquisition Corp VI stock jumped 31% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF Acquisition Corp VI stock jumped 31% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-06 17:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF Acquisition Corp VI stock jumped 31% in premarket trading&nbsp;as&nbsp;YouTube competitor Rumble&nbsp;would&nbsp;go public via SPAC CF Acquisition VI.</p>\n<p><img src=\"https://static.tigerbbs.com/b8dc893dd9a925f906f6e5709286bb79\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Canadian video platform Rumble Inc said&nbsp;it would go public by merging with blank-check firm&nbsp;CF Acquisition Corp VI&nbsp;at an initial enterprise value of $2.1 billion.</p>\n<p>The deal is expected to provide about $400 million in proceeds to Rumble, the company said in a statement.</p>\n<p>Upon the deal's closing, Rumble said founder and Chief Executive Officer Chris Pavlovski will retain voting control.</p>\n<p>The combined company will be called Rumble and is expected to list on the Nasdaq.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191547402","content_text":"CF Acquisition Corp VI stock jumped 31% in premarket trading as YouTube competitor Rumble would go public via SPAC CF Acquisition VI.\n\nCanadian video platform Rumble Inc said it would go public by merging with blank-check firm CF Acquisition Corp VI at an initial enterprise value of $2.1 billion.\nThe deal is expected to provide about $400 million in proceeds to Rumble, the company said in a statement.\nUpon the deal's closing, Rumble said founder and Chief Executive Officer Chris Pavlovski will retain voting control.\nThe combined company will be called Rumble and is expected to list on the Nasdaq.","news_type":1},"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848709368,"gmtCreate":1636025415150,"gmtModify":1636027785724,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"The more truth about this covid situation gets spread out there, the more big corrupt pharmas should dive in the short term.&nbsp;","listText":"The more truth about this covid situation gets spread out there, the more big corrupt pharmas should dive in the short term.&nbsp;","text":"The more truth about this covid situation gets spread out there, the more big corrupt pharmas should dive in the short term.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848709368","repostId":"1114412462","repostType":2,"repost":{"id":"1114412462","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636024828,"share":"https://www.laohu8.com/m/news/1114412462?lang=&edition=full","pubTime":"2021-11-04 19:20","market":"us","language":"en","title":"Pharmaceutical stocks dropped in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1114412462","media":"Tiger Newspress","summary":"Pharmaceutical stocks dropped in premarket trading after Moderna earnings coming in far short of est","content":"<p>Pharmaceutical stocks dropped in premarket trading&nbsp;after&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">Moderna</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">earnings</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">coming</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">in</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">far</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">short</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">of</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">estimates</a>.Moderna,Novavax&nbsp;and&nbsp;BioNTech SE&nbsp;Dived&nbsp;between 4% and 12%.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/22f1d581ec70d04f19c34a0c5a907d67\" tg-width=\"408\" tg-height=\"302\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaceutical stocks dropped in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaceutical stocks dropped in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-04 19:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharmaceutical stocks dropped in premarket trading&nbsp;after&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">Moderna</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">earnings</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">coming</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">in</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">far</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">short</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">of</a>&nbsp;<a href=\"https://laohu8.com/NW/1101079537\" target=\"_blank\">estimates</a>.Moderna,Novavax&nbsp;and&nbsp;BioNTech SE&nbsp;Dived&nbsp;between 4% and 12%.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/22f1d581ec70d04f19c34a0c5a907d67\" tg-width=\"408\" tg-height=\"302\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114412462","content_text":"Pharmaceutical stocks dropped in premarket trading after Moderna earnings coming in far short of estimates.Moderna,Novavax and BioNTech SE Dived between 4% and 12%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864653997,"gmtCreate":1633099274018,"gmtModify":1633099274187,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Rather great news. First aim is to tahan the rest of this year in SG without getting jabbed.","listText":"Rather great news. First aim is to tahan the rest of this year in SG without getting jabbed.","text":"Rather great news. First aim is to tahan the rest of this year in SG without getting jabbed.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864653997","repostId":"2172968435","repostType":4,"repost":{"id":"2172968435","pubTimestamp":1633097043,"share":"https://www.laohu8.com/m/news/2172968435?lang=&edition=full","pubTime":"2021-10-01 22:04","market":"us","language":"en","title":"Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News","url":"https://stock-news.laohu8.com/highlight/detail?id=2172968435","media":"Investing.com","summary":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in pre","content":"<p>By Geoffrey Smith</p>\n<p>Investing.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.</p>\n<p>By (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.&nbsp; Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.</p>\n<p>Merck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.</p>\n<p>The study was stopped early, as is often the case when an experimental drug shows signs of efficacy.</p>\n<p>Scientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.</p>\n<p>Related Articles</p>\n<p>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</p>\n<p>Stocks under pressure as euro zone inflation hits 13-year high</p>\n<p>Merck's COVID-19 pill cuts risk of death, hospitalization by 50% in study</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","MRK":"默沙东","NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2172968435","content_text":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.\nBy (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.  Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.\nMerck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.\nThe study was stopped early, as is often the case when an experimental drug shows signs of efficacy.\nScientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.\nRelated Articles\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\nStocks under pressure as euro zone inflation hits 13-year high\nMerck's COVID-19 pill cuts risk of death, hospitalization by 50% in study","news_type":1},"isVote":1,"tweetType":1,"viewCount":461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853129068,"gmtCreate":1634781048703,"gmtModify":1634781051103,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like near you","listText":"Like near you","text":"Like near you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853129068","repostId":"1181020907","repostType":4,"repost":{"id":"1181020907","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634769732,"share":"https://www.laohu8.com/m/news/1181020907?lang=&edition=full","pubTime":"2021-10-21 06:42","market":"us","language":"en","title":"Tesla beats Q3 revenue estimates but supply-chain problems impacting factories","url":"https://stock-news.laohu8.com/highlight/detail?id=1181020907","media":"Tiger Newspress","summary":"Tesla Inc on Wednesday beat Wall Street expectations for third-quarter revenue on the back of record deliveries as the electric car maker navigated through a prolonged global shortage of chips and raw materials.Tesla said it aims to increase production in the fourth quarter from the previous quarter, adding that \"the magnitude of growth will be determined largely by outside factors.\". Tesla, the world's most valuable automaker, has weathered the pandemic and the global supply-chain crisis better","content":"<p>Tesla Inc&nbsp;on Wednesday beat Wall Street expectations for third-quarter revenue on the back of record deliveries as the electric car maker navigated through a prolonged global shortage of chips and raw materials.</p>\n<p>Tesla said it aims to increase production in the fourth quarter from the previous quarter, adding that \"the magnitude of growth will be determined largely by outside factors.\"</p>\n<p>\"A variety of challenges, including semiconductor shortages, congestion at ports and rolling blackouts, have been impacting our ability to keep factories running at full speed,\" the company said.</p>\n<p>Tesla, the world's most valuable automaker, has weathered the pandemic and the global supply-chain crisis better than rivals, posting record revenue for the fifth consecutive quarter in the July to September period, fueled by a production ramp-up at its Chinese factory.</p>\n<p>Led by billionaire Elon Musk, Tesla faces challenges of maintaining its growth in the face of a prolonged chip shortage, with its factories starting production in Berlin and Texas this year.</p>\n<p>Tesla shares, up about 23% this year, were down about 1.6% in extended trade late on Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/d998d6369e593952a4c3d57b9224c4a6\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Revenue rose to $13.76 billion from $8.77 billion a year earlier. Analysts had expected revenue of about $13.63 billion, according to IBES data from Refinitiv.</p>\n<p>Tesla's automotive gross margin, excluding environmental credits, rose to 28.8%, from 25.8% the previous quarter.</p>\n<p>Tesla has been raising prices in the United States, which helped cushion the impact of the supply-chain costs, analysts said.</p>\n<p>\"Tesla's average selling price (ASP) of vehicles were higher than expected and the U.S. market drove that,\" said Gene Munster, managing partner at venture capital firm Loup Ventures, an investor in Tesla. Tesla said its ongoing cost-cutting efforts helped counter the declines in its ASPs stemming from sales of lower-priced vehicles like the Model 3 and Model Y.</p>\n<p>Tesla has cut costs with the use of more Chinese parts including batteries. The company posted robust sales in China, where its Shanghai factory has surpassed the Tesla factory in Fremont, California, in terms of production.</p>\n<p><img src=\"https://static.tigerbbs.com/bdf4574208dc79952acb2a1ca49c22b2\" tg-width=\"960\" tg-height=\"582\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla beats Q3 revenue estimates but supply-chain problems impacting factories</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla beats Q3 revenue estimates but supply-chain problems impacting factories\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-21 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla Inc&nbsp;on Wednesday beat Wall Street expectations for third-quarter revenue on the back of record deliveries as the electric car maker navigated through a prolonged global shortage of chips and raw materials.</p>\n<p>Tesla said it aims to increase production in the fourth quarter from the previous quarter, adding that \"the magnitude of growth will be determined largely by outside factors.\"</p>\n<p>\"A variety of challenges, including semiconductor shortages, congestion at ports and rolling blackouts, have been impacting our ability to keep factories running at full speed,\" the company said.</p>\n<p>Tesla, the world's most valuable automaker, has weathered the pandemic and the global supply-chain crisis better than rivals, posting record revenue for the fifth consecutive quarter in the July to September period, fueled by a production ramp-up at its Chinese factory.</p>\n<p>Led by billionaire Elon Musk, Tesla faces challenges of maintaining its growth in the face of a prolonged chip shortage, with its factories starting production in Berlin and Texas this year.</p>\n<p>Tesla shares, up about 23% this year, were down about 1.6% in extended trade late on Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/d998d6369e593952a4c3d57b9224c4a6\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Revenue rose to $13.76 billion from $8.77 billion a year earlier. Analysts had expected revenue of about $13.63 billion, according to IBES data from Refinitiv.</p>\n<p>Tesla's automotive gross margin, excluding environmental credits, rose to 28.8%, from 25.8% the previous quarter.</p>\n<p>Tesla has been raising prices in the United States, which helped cushion the impact of the supply-chain costs, analysts said.</p>\n<p>\"Tesla's average selling price (ASP) of vehicles were higher than expected and the U.S. market drove that,\" said Gene Munster, managing partner at venture capital firm Loup Ventures, an investor in Tesla. Tesla said its ongoing cost-cutting efforts helped counter the declines in its ASPs stemming from sales of lower-priced vehicles like the Model 3 and Model Y.</p>\n<p>Tesla has cut costs with the use of more Chinese parts including batteries. The company posted robust sales in China, where its Shanghai factory has surpassed the Tesla factory in Fremont, California, in terms of production.</p>\n<p><img src=\"https://static.tigerbbs.com/bdf4574208dc79952acb2a1ca49c22b2\" tg-width=\"960\" tg-height=\"582\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181020907","content_text":"Tesla Inc on Wednesday beat Wall Street expectations for third-quarter revenue on the back of record deliveries as the electric car maker navigated through a prolonged global shortage of chips and raw materials.\nTesla said it aims to increase production in the fourth quarter from the previous quarter, adding that \"the magnitude of growth will be determined largely by outside factors.\"\n\"A variety of challenges, including semiconductor shortages, congestion at ports and rolling blackouts, have been impacting our ability to keep factories running at full speed,\" the company said.\nTesla, the world's most valuable automaker, has weathered the pandemic and the global supply-chain crisis better than rivals, posting record revenue for the fifth consecutive quarter in the July to September period, fueled by a production ramp-up at its Chinese factory.\nLed by billionaire Elon Musk, Tesla faces challenges of maintaining its growth in the face of a prolonged chip shortage, with its factories starting production in Berlin and Texas this year.\nTesla shares, up about 23% this year, were down about 1.6% in extended trade late on Wednesday.\n\nRevenue rose to $13.76 billion from $8.77 billion a year earlier. Analysts had expected revenue of about $13.63 billion, according to IBES data from Refinitiv.\nTesla's automotive gross margin, excluding environmental credits, rose to 28.8%, from 25.8% the previous quarter.\nTesla has been raising prices in the United States, which helped cushion the impact of the supply-chain costs, analysts said.\n\"Tesla's average selling price (ASP) of vehicles were higher than expected and the U.S. market drove that,\" said Gene Munster, managing partner at venture capital firm Loup Ventures, an investor in Tesla. Tesla said its ongoing cost-cutting efforts helped counter the declines in its ASPs stemming from sales of lower-priced vehicles like the Model 3 and Model Y.\nTesla has cut costs with the use of more Chinese parts including batteries. The company posted robust sales in China, where its Shanghai factory has surpassed the Tesla factory in Fremont, California, in terms of production.","news_type":1},"isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":191943320,"gmtCreate":1620836935760,"gmtModify":1631888757214,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VIOT\">$Viomi Technology Co.(VIOT)$</a>[流泪]&nbsp;","listText":"<a href=\"https://laohu8.com/S/VIOT\">$Viomi Technology Co.(VIOT)$</a>[流泪]&nbsp;","text":"$Viomi Technology Co.(VIOT)$[流泪]","images":[{"img":"https://static.tigerbbs.com/0e0c80ecfd4fab811596505698014851","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/191943320","isVote":1,"tweetType":1,"viewCount":1276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":602303058,"gmtCreate":1638966793507,"gmtModify":1638968906662,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Anything coming from Pfizer is bs at this point. We need actual peer reviewed studies published publicly from actual scientists for accurate information. This is just them winning back the market's confidence and persuading nations to order 3rd jabs for more profit$.","listText":"Anything coming from Pfizer is bs at this point. We need actual peer reviewed studies published publicly from actual scientists for accurate information. This is just them winning back the market's confidence and persuading nations to order 3rd jabs for more profit$.","text":"Anything coming from Pfizer is bs at this point. We need actual peer reviewed studies published publicly from actual scientists for accurate information. This is just them winning back the market's confidence and persuading nations to order 3rd jabs for more profit$.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602303058","repostId":"1177589023","repostType":2,"repost":{"id":"1177589023","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohu8.com/m/news/1177589023?lang=&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1},"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861696598,"gmtCreate":1632490537414,"gmtModify":1632717966740,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>bloodshed","listText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>bloodshed","text":"$STI ETF(ES3.SI)$bloodshed","images":[{"img":"https://static.tigerbbs.com/ce8180f7add6d5d3a728b0731b072ed7","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861696598","isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":840946057,"gmtCreate":1635580088005,"gmtModify":1635580088005,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Niiice","listText":"Niiice","text":"Niiice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840946057","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840084280,"gmtCreate":1635568727401,"gmtModify":1635568743175,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/A35.SI\">$ABF SG BOND ETF(A35.SI)$</a>sg is garbage","listText":"<a href=\"https://laohu8.com/S/A35.SI\">$ABF SG BOND ETF(A35.SI)$</a>sg is garbage","text":"$ABF SG BOND ETF(A35.SI)$sg is garbage","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840084280","isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855596967,"gmtCreate":1635381615759,"gmtModify":1635381615823,"author":{"id":"3579827147050987","authorId":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Seriously last night insider pump and dump?&nbsp;<a href=\"https://laohu8.com/S/ASTS\">$AST SpaceMobile, Inc.(ASTS)$</a>","listText":"Seriously last night insider pump and dump?&nbsp;<a href=\"https://laohu8.com/S/ASTS\">$AST SpaceMobile, Inc.(ASTS)$</a>","text":"Seriously last night insider pump and dump? $AST SpaceMobile, Inc.(ASTS)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855596967","isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}